Bovine lactoferrin induces interleukin-11 production in a hepatitis mouse model and human intestinal myofibroblasts

European Journal of Nutrition

Volumn 51, Issue 3, 2012, Pages 343-351

  Kuhara, Tetsuya ^a   Yamauchi, Koji ^a   Iwatsuki, Keiji ^a  

^a MORINAGA MILK INDUSTRY CO LTD   (Japan)

Author keywords

Anti inflammatory factor; Bone morphogenetic protein 2; Interleukin 11; Lactoferrin

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; INTERLEUKIN 11; LACTOFERRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROTECTION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TRANSPORT; EPITHELIUM CELL; HEPATITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CELL; INTESTINE MUCOSA; LIVER FAILURE; LIVER PROTECTION; MALE; MONOCYTE; MOUSE; MYOFIBROBLAST; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE MORPHOGENETIC PROTEIN 2; CACO-2 CELLS; CATTLE; DISEASE MODELS, ANIMAL; HEPATITIS; HUMANS; INTERLEUKIN-11; INTESTINAL MUCOSA; LACTOFERRIN; MICE; MICE, INBRED BALB C; MYOFIBROBLASTS;

ANIMALIA; BOVINAE;

EID: 84860654833     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-011-0219-y     Document Type: Article

References (33)

1. Brock JH (2002) The physiology of lactoferrin. Biochem Cell Biol 80:1-6 (Pubitemid 34194221)
2. Lönnerdal B (2009) Nutritional roles of lactoferrin. Curr Opin Clin Nutr Metab Care 12:293-297
3. Tanaka K, Ikeda M, Nozaki A et al (1999) Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn J Cancer Res 90:367-371 (Pubitemid 29213539)
4. Iwasa M, Kaito M, Ikoma J et al (2002) Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. Am J Gastroenterol 97:766-767 (Pubitemid 34245920)
5. Okada S, Tanaka K, Sato T et al (2002) Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn J Cancer Res 93:1063-1069 (Pubitemid 35154274)
6. Konishi M, Iwasa M, Yamauchi K et al (2006) Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol Res 36:27-32 (Pubitemid 44309286)
7. Yamauchi K, Hiruma M, Yamazaki N et al (2000) Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study. Mycoses 43:197-202
8. Kozu T, Iinuma G, Ohashi Y et al (2009) Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res 2:975-983
9. Kuwata H, Yamauchi K, Teraguchi S et al (2001) Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats. J Nutr 131:2121-2127 (Pubitemid 32720641)
10. Togawa J, Nagase H, Tanaka K et al (2002) Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J Physiol Gastrointest Liver Physiol 283:G187-G195 (Pubitemid 34666177)
11. Tsubota A, Yoshikawa T, Nariai K et al (2008) Bovine lactoferrin potently inhibits liver mitochondrial 8-OHdG levels and retrieves hepatic OGG1 activities in long-evans Cinnamon rats. J Hepatol 48:486-493
12. Horiuchi Y, Higuchi T, Tatsumi K et al (2009) Lactoferrin is associated with a decrease in oocyte depletion in mice receiving cyclophosphamide. Fertil Steril 91:2069-2078
13. Kuhara T, Yamauchi K, Tamura Y et al (2006) Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J Interf Cytok Res 26:489-499 (Pubitemid 44061089)
14. Kuhara T, Iigo M, Itoh T et al (2000) Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 38:192-199 (Pubitemid 32762019)
15. Du X, Williams DA (1997) Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89:3897-3908 (Pubitemid 27220932)
16. Trepicchio WL, Wang L, Bozza M et al (1997) IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J Immunol 159:5661-5670 (Pubitemid 127470321)
17. Ropeleski MJ, Tang J, Walsh-Reitz MM et al (2003) Interleukin-11-induced heat shock protein 25 confers intestinal epithelialspecific cytoprotection from oxidant stress. Gastroenterology 124:1358-1368 (Pubitemid 36531810)
18. Ellis M, Zwaan F, Hedström U et al (2003) Recombinant human interleukin 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy: a doubleblind placebo-controlled randomized trial. Lancet 361:275-280 (Pubitemid 36126186)
19. Sands BE, Bank S, Sninsky CA et al (1999) Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 117:58-64 (Pubitemid 29297620)
20. Sands BE, Winston BD, Salzberg B et al (2002) Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 16:399-406 (Pubitemid 34214518)
21. Lawitz EJ, Hepburn MJ, Casey TJ (2004) A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. Am J Gastroenterol 99:2359-2364 (Pubitemid 40039366)
22. Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22:233-241 (Pubitemid 40136452)
23. Hardwick JC, Van Den Brink GR, Bleuming SA et al (2004) Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 126:111-121 (Pubitemid 38040729)
24. Nakatsuka R, Taniguchi M, Hirata M et al (2007) Transient expression of bone morphogenetic protein-2 in acute liver injury by carbon tetrachloride. J Biochem 141:113-119
25. Yamaguchi M, Matsuura M, Kobayashi K et al (2001) Lactoferrin protects against development of hepatitis caused by sensitization of Kupffer cells by lipopolysaccharide. Clin Diagn Lab Immunol 8:1234-1239 (Pubitemid 33035761)
26. Blais A, Malet A, Mikogami T et al (2009) Oral bovine lactoferrin improves bone status of ovariectomizes mice. Am J Physiol Endocrinol Metab 296:E1281-E1288
27. Powell DW, Mifflin RC, Valentich JD et al (1999) Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 277:C183-C201 (Pubitemid 29415032)
28. Mikogami T, Heyman M, Spik G et al (1994) Apical-to-basolateral transepithelial transport of human lactoferrin in the intestinal cell line HT-29 cl.19A. Am J Physiol 267:G308-G315
29. Trepicchio WL, Ozawa M, Walters IB et al (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104:1527-1537 (Pubitemid 30002364)
30. Manzoni P, Rinaldi M, Cattani S et al (2009) Bovine lactoferrin supplementation for prevention of late-onset sepsis in very lowbirth-weight neonates: a randomized trial. JAMA 302:1421-1428
31. Qiu BS, Pfeiffer CJ, Keith JC Jr (1996) Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 41:1625-1630 (Pubitemid 26285750)
32. Bozza M, Bliss JL, Maylor R et al (1990) Interleukin-11 reduces T-cell-dependent experimental liver injury in mice. Hepatology 30:1441-1447
33. Hori M, Sawai H, Tsuji Y et al (2006) Bone morphogenetic protein-2 counterregulates interleukin-18 mRNA and protein in MC3T3-E1 mouse osteoblastic cells. Connect Tissue Res 47:124-132 (Pubitemid 43860233)